Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells $63,424.20 in Stock

Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Richard C. Malabre sold 30,202 shares of Akebia Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total value of $63,424.20. Following the transaction, the chief accounting officer now owns 280,248 shares in the company, valued at approximately $588,520.80. The trade was a 9.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Akebia Therapeutics Stock Performance

AKBA opened at $2.17 on Thursday. The stock has a market capitalization of $473.45 million, a PE ratio of -9.43 and a beta of 0.74. Akebia Therapeutics, Inc. has a one year low of $0.80 and a one year high of $2.48. The business’s 50 day moving average price is $2.00 and its 200 day moving average price is $1.67.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The firm had revenue of $37.43 million during the quarter, compared to analyst estimates of $45.66 million. During the same quarter in the previous year, the business posted ($0.08) earnings per share. As a group, equities research analysts forecast that Akebia Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AKBA. SRS Capital Advisors Inc. acquired a new stake in shares of Akebia Therapeutics during the fourth quarter valued at about $26,000. Wealth Effects LLC boosted its position in shares of Akebia Therapeutics by 18.5% during the 4th quarter. Wealth Effects LLC now owns 32,000 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 5,000 shares during the period. Empirical Asset Management LLC acquired a new stake in Akebia Therapeutics in the 3rd quarter valued at approximately $44,000. AlphaMark Advisors LLC purchased a new stake in Akebia Therapeutics in the fourth quarter valued at approximately $73,000. Finally, B. Riley Wealth Advisors Inc. purchased a new stake in Akebia Therapeutics in the second quarter valued at approximately $44,000. Institutional investors and hedge funds own 33.92% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $7.50 price target on shares of Akebia Therapeutics in a report on Thursday, January 23rd. StockNews.com cut shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.